Loading clinical trials...
Loading clinical trials...
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (TRIDENT)
Conditions
Interventions
Relacorilant 150 mg once daily (QD)
Nab-paclitaxel 100 mg/m^2
+1 more
Locations
10
United States
Site 02
Scottsdale, Arizona, United States
Site 04
Los Angeles, California, United States
Site 06
Atlanta, Georgia, United States
Site 03
Grand Rapids, Michigan, United States
Site 10
East Brunswick, New Jersey, United States
Site 08
Albany, New York, United States
Start Date
January 27, 2026
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
April 23, 2026
NCT06844383
NCT02600949
NCT06340711
NCT06921928
NCT06423326
NCT07542041
Lead Sponsor
Corcept Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions